Becton, Dickinson(US:BDX) Yahoo Finance·2025-11-17 14:14Market Overview - The US equity market experienced a rally in the third quarter of 2025, with the S&P 500 Index increasing by 8.12% [1] - Bonds also performed well, with the Bloomberg U.S. Aggregate Bond Index rising by 2.03% during the same period [1] Performance Analysis - The composite return for the quarter was 7.22% gross of fees and 7.10% net of fees, which underperformed the S&P 500 Index's gain of 8.12% [1] - The underperformance of the strategy was attributed to security selection [1] Company Focus: Becton, Dickinson and Company (NYSE: BDX) - Becton, Dickinson and Company is a healthcare company involved in the development and manufacturing of medical supplies and diagnostic products [2] - The stock had a one-month return of 1.07% but lost 13.86% of its value over the past 52 weeks, closing at $193.04 per share with a market capitalization of $55.33 billion on November 14, 2025 [2] Recent Developments - The company faced challenges due to recent fiscal earnings results, which were negatively impacted by funding cuts from the National Institutes of Health (NIH) [3] - Becton, Dickinson and Company lowered its forward earnings and revenue guidance, citing weaknesses in biosciences R&D funding and the effects of tariffs [3] - The company is attempting to divest its Biosciences and Diagnostic Solutions divisions, but there are concerns about achieving optimal value due to the cyclical downturn in these sectors [3] Investment Sentiment - Becton, Dickinson and Company was held by 58 hedge fund portfolios at the end of the second quarter of 2025, an increase from 54 in the previous quarter [4] - Despite its potential, analysts suggest that certain AI stocks may offer better upside potential and lower downside risk compared to Becton, Dickinson and Company [4] - The company's revenue grew by 7% to $5.9 billion in the fiscal fourth quarter of 2025, with a 3.9% organic growth rate [4]